The Anti Aging Backlash: Are We Optimising Our Health and Forgetting to Live?
Supplements. Peptides. Protein-maxxing. Zone 2 training. Biological-age tests. Therapeutic plasma exchange. Off-label medications. Wearables tracking almost every measurable aspect of our biology.
The modern longevity movement promises something extraordinary: the possibility of extending not just lifespan, but the years we remain healthy, independent and mentally sharp. Yet an important question is emerging. Are we becoming so preoccupied with extending life that we are forgetting how to live it?
Longevity has grown into a major commercial opportunity, attracting pharmaceutical companies, biotechnology investors, wellness entrepreneurs, researchers and direct-to-consumer health businesses. Some developments are scientifically promising. Others remain experimental, while some commercial claims have moved far ahead of the available evidence.
The growing backlash is therefore worth examining.
Three books published in the past year capture a growing sentiment that a myopic pursuit of longevity is unrealistic, misguided and potentially harmful. Physician and bioethicist Ezekiel Emanuel (1) argues that meaningful relationships and quality of life should matter more than simply accumulating years. Registered dietitian Debra Benfield (2) challenges the ageism and body dissatisfaction embedded in the anti-ageing and wellness industries. Scientist Saul Newman (3) questions the reliability of some longevity research, particularly historical age records, demographic statistics and commercially influenced science.Their perspectives raise an important question: How much of the modern longevity movement is genuinely improving human health, and how much is selling the promise of a younger, longer life?
The answer is not to abandon longevity research or preventive medicine.
Exercise, adequate nutrition, sleep, cardiovascular health, metabolic health, vaccination and meaningful social relationships remain important foundations of healthy ageing. Emerging medical interventions also deserve investigation, provided their benefits and risks are established through rigorous research.
But a change in a biological-age test is not necessarily an extension of healthy life. A promising laboratory result is not a proven clinical benefit. And a costly intervention is not automatically better than the fundamentals.
Perhaps the most sensible goal is not to live to 120 at any cost, but to increase the likelihood of reaching our 80s or 90s with our health, independence, relationships and enjoyment of life intact.
The real objective should be to add life to our years, not merely years to our lives.
1. Three Books Challenging the Longevity Industry
Three books published between late 2025 and 2026 capture different aspects of the growing debate about longevity culture, ageing and the commercialisation of health.
1.1 Eat Your Ice Cream: Six Simple Rules for a Long and Healthy Life — Ezekiel Emanuel
Dr. Ezekiel Emanuel, an oncologist and professor of medical ethics and health policy at the University of Pennsylvania, challenges society's growing fixation on longevity.
His argument is not that people should abandon healthy habits or preventive medicine. Rather, he questions the idea that living longer should become the overriding objective of life.
In his view, the pursuit of longevity can become an obsession that encourages people to spend excessive time and money trying to optimise every aspect of their biology while neglecting relationships, purpose and everyday enjoyment.
One of his most important arguments is that meaningful relationships should have a much more prominent place in our understanding of health and longevity.
His criticism of Peter Attia's Outlive should, however, be interpreted fairly. Attia does devote an entire chapter, Chapter 17, titled Work in Progress: The High Price of Ignoring Emotional Health, to emotional health. Emanuel's disagreement is better understood as a difference in emphasis: he believes relationships and meaning deserve a more central position.
Emanuel's practical message is relatively straightforward:
- Exercise regularly and maintain physical function.
- Eat a nutritious and sustainable diet.
- Prioritise adequate sleep.
- Keep the mind active.
- Avoid destructive behaviours.
- Invest in meaningful relationships and activities.
His personal views about refusing certain life-extending interventions after age 75 are an ethical preference, not a general medical recommendation. There is no universal age at which appropriate medical treatment should automatically stop.
The takeaway: A longer life is not necessarily a better life. Health optimisation should support meaningful living, not replace it.
1.2 Unapologetic Aging: How to Mend and Nourish Your Relationship with Your Body — Debra Benfield
Debra Benfield, a registered dietitian with extensive experience in eating disorder recovery, challenges the anti-ageing industry's messaging, particularly when directed at women experiencing perimenopause, menopause and later-life changes.
She argues that modern healthy-ageing marketing can become another version of diet culture.
Women are increasingly encouraged to interpret natural changes in body composition, weight distribution and physical appearance as problems that must be corrected through supplements, restrictive diets and increasingly demanding exercise programmes.
Some of these interventions have legitimate health objectives. Maintaining muscle mass, preventing osteoporosis and protecting cardiovascular health are important. However, the problem arises when the language of prevention is used to promote unrealistic expectations about remaining permanently thin, youthful or physically unchanged.
Benfield encourages women to develop a more accepting and compassionate relationship with their changing bodies.
This does not mean abandoning preventive healthcare. It means distinguishing between genuine medical needs and commercial messages that turn normal ageing into a personal failure.
Research also suggests that perceived age discrimination is associated with poorer health outcomes. In a six-year prospective analysis of the English Longitudinal Study of Ageing, perceived age discrimination was associated with increased odds of several incident health conditions. These findings are observational and do not establish that body dissatisfaction directly causes chronic illness.
The takeaway: Healthy ageing should be about maintaining health, function and independence, not trying to look perpetually young.
1.3 Morbid: Debunking Modern Longevity Science — Saul Newman
Scientist Saul Newman has become a prominent critic of aspects of modern longevity research, particularly studies involving exceptionally old people and so-called Blue Zones.
His central argument is that some longevity research relies on demographic data that may contain inaccurate birth records, identity errors, incomplete documentation and, in some cases, fraud.
He argues that unreliable data can lead researchers to draw incorrect conclusions about the characteristics associated with exceptional longevity.
He also raises concerns about conflicts of interest in the longevity industry, where scientists may simultaneously publish research, advise companies, hold investments or promote products based on the science they study.
These concerns deserve attention. However, criticism of individual datasets or commercial practices should not automatically invalidate the broader field of ageing research.
His criticisms also require independent evaluation. For example, the 2017 peer-reviewed age-verification study of Jiroemon Kimura found inconsistencies in certain historical records but concluded that no critical discrepancies were identified. The investigators verified that Kimura lived to 116 years and 54 days.
The takeaway: Longevity research requires reliable demographic records, reproducible findings, transparent funding and independent validation. Scientific credibility should never be a substitute for scientific evidence.
2. Fact-Checking the Longevity Debate
Several criticisms raised by Newman are important, but the details matter. Scientific scepticism should apply equally to longevity claims and to claims made by critics of longevity research.
2.1 Jiroemon Kimura: Were the world's oldest ages accurately recorded?
Jiroemon Kimura of Japan died in 2013 at the recorded age of 116 years.
His historical records reportedly contained several inconsistencies, including mismatches between documents and personal accounts of past events.
However, the 2017 study Age Verification of the Longest Lived Man in the World, published in Experimental Gerontology, examined official documentation, non-official records and historical events.
The researchers identified inconsistencies but concluded that there were no critical discrepancies and verified his age.
This distinction is important: inconsistent historical records do not automatically prove that an age claim is fraudulent.
Reference: Age Verification of the Longest Lived Man in the World (2017).
2.2 Japan's Missing Centenarians: Did the Discovery Invalidate Longevity Statistics?
In 2010, Japan discovered that 234,354 people who should have been at least 100 years old remained on family registers without having been officially removed.
This raised important questions about demographic records and the verification of exceptionally old individuals.
However, a subsequent analysis published in Demographic Research in 2012 examined the issue and concluded that the missing-centenarian records had an effectively negligible impact on official life-expectancy statistics.
Therefore, while the administrative failures were serious, it would be misleading to suggest that Japan's national life-expectancy figures were fundamentally fabricated.
Reference: The Mystery of Japan's Missing Centenarians Explained (2012).
2.3 Are Blue Zones Real?
Newman has questioned the reliability of historical age records used to identify Blue Zones, regions associated with unusually high concentrations of nonagenarians and centenarians.
His concerns include documentation errors, mistaken identities and the possibility that some people recorded as exceptionally old may have died decades earlier.
These are legitimate methodological questions. However, they should not be confused with proof that all Blue Zone research is invalid.
A 2025 paper in The Gerontologist, titled The Validity of Blue Zones Demography: A Response to Critiques, described the age-verification methods used in Blue Zones research and argued that the relevant datasets had been extensively validated through independent documents and demographic methods.
This paper presents the researchers' defence of the datasets. It is useful evidence in the debate, but should also be considered alongside independent scrutiny.
There is an additional distinction: historical longevity patterns do not necessarily mean that the same populations retain their original health advantages today. Migration, diet, physical activity, socioeconomic changes and generational differences can all influence health outcomes.
Reference: The Validity of Blue Zones Demography: A Response to Critiques (2025).
3. Not All Longevity Interventions Are Created Equal
This is perhaps the most important scientific distinction missing from much of the longevity debate.
Supplements, peptides, protein-maxxing, Zone 2 training, therapeutic plasma exchange, off-label drugs and biological-age tests are often presented together as components of the modern longevity movement.
But they occupy very different positions on the evidence spectrum.
An intervention can have a plausible biological mechanism without demonstrating meaningful clinical benefit. Equally, an established medical treatment can be appropriate for a disease without being justified as a general anti-ageing intervention.
A Practical Longevity Evidence Framework
| Evidence category | Examples | Interpretation |
|---|---|---|
| Level 1: Established health foundations | Aerobic exercise, resistance training, adequate nutrition, sleep, smoking cessation, vaccination and management of cardiovascular risk factors. | Strong evidence supports their role in preventing disease, maintaining function and improving health. |
| Level 2: Evidence-based medical interventions | Statins, antihypertensives and GLP-1 medicines when clinically indicated. | Evidence of benefit for specific patient populations and clinical indications. Not automatically general anti-ageing treatments. |
| Level 3: Emerging longevity interventions | Rapamycin, metformin for longevity in otherwise healthy people, senolytics, experimental peptides and biological-age modification. | Promising mechanisms or early findings, but insufficient evidence to establish longer or healthier lives in humans. |
| Level 4: Commercially promoted experimental procedures | Therapeutic plasma exchange for rejuvenation, unvalidated biological-age testing packages and unsupported supplement combinations. | Clinical longevity benefits remain unproven. Claims should be evaluated carefully before patients spend money or accept medical risks. |
Important: This is an editorial framework for evaluating longevity claims, not a formal clinical evidence-grading system. The evidence category of an intervention may change depending on its indication, population and demonstrated outcomes.
3.1 Protein-Maxxing: More Is Not Always Better
Protein is essential for maintaining muscle mass, strength and physical function as we age.
However, consuming the maximum possible amount is not necessarily beneficial.
The PROT-AGE Study Group recommends approximately 1.0–1.2 grams of protein per kilogram of body weight daily for many healthy older adults. Higher amounts may be appropriate for physically active individuals or people recovering from illness. People with severe kidney disease may require individualised dietary recommendations.
Protein intake should be considered alongside:
- Progressive resistance exercise.
- Adequate total calorie intake.
- Protein quality and distribution across meals.
- Overall nutritional status.
- Individual health conditions and kidney function.
The objective is not to win a protein-consumption competition. It is to maintain muscle, strength and independence.
3.2 Zone 2 Training: Useful, but Not a Magic Formula
Physical activity is among the most consistently supported interventions for healthy ageing.
Zone 2 training has attracted attention because it provides a structured approach to aerobic conditioning. However, it should not be presented as the only or uniquely validated exercise intensity for longevity.
A sustainable exercise programme should incorporate:
- Aerobic exercise to improve cardiovascular fitness.
- Progressive resistance training to preserve muscle and strength.
- Balance and mobility exercises to maintain physical independence.
- Activities that are enjoyable and sustainable over the long term.
Consistency is more important than becoming obsessed with one particular training zone.
3.3 Therapeutic Plasma Exchange: Established Medical Procedure, Unproven Longevity Application
Therapeutic plasma exchange (TPE), sometimes marketed in wellness settings as a plasma rejuvenation procedure, involves removing a patient's plasma and replacing it with an appropriate replacement fluid.
It has established medical applications in certain autoimmune, neurological, haematological and other conditions.
However, its use for rejuvenation or extending lifespan is a different proposition.
The fact that plasma contains circulating proteins, inflammatory mediators and other biological molecules does not establish that removing and replacing plasma reverses ageing or extends human lifespan.
The American Society for Apheresis published its tenth special issue of clinical practice guidelines in September 2026. These guidelines review evidence-based indications for therapeutic apheresis in human disease. They should not be interpreted as establishing TPE as an anti-ageing treatment.
Until controlled human studies demonstrate meaningful improvements in clinical outcomes, TPE for longevity should be regarded as experimental rather than established preventive medicine.
Reference: American Society for Apheresis: Tenth Special Issue of Guidelines on Therapeutic Apheresis (2026).
3.4 Supplements, Peptides and Off-Label Drugs
The longevity market contains many substances with interesting biological mechanisms, including compounds associated with cellular senescence, mitochondrial function, nutrient sensing and inflammation.
Some have demonstrated promising findings in laboratory experiments or animal models. Others have progressed into early human studies.
However, several important questions remain:
- Does the intervention improve a clinically meaningful outcome in humans?
- Does it reduce disease incidence or disability?
- Does it improve healthspan or merely change a biomarker?
- Are the long-term risks known?
- Does the potential benefit justify the cost and treatment burden?
For example, rapamycin has attracted interest because of its effects on the mTOR pathway and lifespan in several animal models. However, this does not establish that taking rapamycin will extend the lifespan of otherwise healthy humans.
Likewise, metformin has important clinical applications in diabetes, but its use specifically to extend lifespan in people without an established indication remains an area of investigation.
Biological plausibility is a reason to investigate an intervention, not a reason to automatically recommend it.
4. The Missing Pillar of Longevity: Relationships and Social Connection
One of Emanuel's strongest arguments is that relationships should be considered an integral component of healthy ageing rather than an optional lifestyle extra.
There is meaningful epidemiological research supporting this perspective.
A 2023 systematic review and meta-analysis published in Nature Human Behaviour examined 90 prospective cohort studies involving approximately 2.2 million individuals.
The researchers reported that:
- Social isolation was associated with a 32% higher risk of all-cause mortality.
- Loneliness was associated with a 14% higher risk of all-cause mortality.
These findings demonstrate associations, not proof that social connection itself causes those precise reductions in mortality. Nevertheless, they provide substantial evidence that social relationships deserve greater attention in public health and healthy-ageing strategies.
Meaningful relationships may contribute to health through several pathways:
- Emotional support and reduced psychological distress.
- Greater motivation to maintain healthy habits.
- More opportunities for physical and social activity.
- Earlier recognition of health problems.
- A greater sense of purpose and belonging.
Longevity should therefore include more than physical measurements and laboratory results.
Having someone to share a meal, a conversation, a walk or an ordinary day with may be just as important to a fulfilling life as the latest optimisation strategy.
5. Ageing, Body Image and the Psychology of Wellness
Benfield's argument highlights another issue: the growing tendency to present normal ageing as something that must be constantly corrected.
Many ageing-related changes are biologically normal. Changes in body composition, skin elasticity, muscle mass, metabolism and hormonal function do not automatically indicate disease.
At the same time, certain age-related changes can increase the risk of clinically important conditions. Osteoporosis, sarcopenia, cardiovascular disease and metabolic dysfunction deserve appropriate attention.
The distinction is between caring for the ageing body and treating the ageing body as a failure.
Ageism and Health
A prospective analysis of the English Longitudinal Study of Ageing found that perceived age discrimination was associated with deterioration in self-rated health and increased odds of several chronic conditions over six years.
These results are important but should not be exaggerated into a simple causal claim that negative attitudes about ageing directly cause inflammation and chronic disease. Social, behavioural and biological factors may interact.
The broader message is clear: healthy ageing should not be reduced to appearance, body weight or a biological-age number.
6. The Longevity Industry and Conflicts of Interest
Newman's criticism of commercial conflicts of interest raises an important issue for the scientific credibility of longevity research.
Many researchers work across academia, biotechnology companies, start-ups, advisory boards, investment funds and commercial health businesses.
Such involvement is not automatically inappropriate. Commercial partnerships can help translate scientific discoveries into treatments and technologies.
However, financial interests should be disclosed and independently scrutinised.
David Sinclair, a prominent Harvard-affiliated ageing researcher, provides a useful example of why transparency matters. His laboratory maintains a public list of past and present affiliations, including advisory roles, investments, company involvement and other professional interests.
The laboratory's disclosure page also explains that the list is informational rather than a formal or necessarily exhaustive record.
Rather than automatically dismissing a researcher's work because of commercial involvement, readers should ask the following questions:
- Financial interests: Does the researcher have an ownership, investment or advisory relationship with the company selling the intervention?
- Disclosure: Are these relationships clearly and transparently reported?
- Independent replication: Have other research groups reproduced the findings?
- Human evidence: Have meaningful clinical outcomes been demonstrated in appropriately designed trials?
- Commercial claims: Does the product promise more than the underlying research actually supports?
Conflicts of interest do not automatically invalidate research, but they increase the importance of transparent methodology, independent verification and evidence-based conclusions.
Reference: David A. Sinclair's Affiliations — The Sinclair Lab.
7. What Does Science Actually Support About Healthy Ageing?
The growing backlash against longevity maximalism should not obscure the substantial scientific value of preventive medicine and ageing research.
The objective should be to prioritise interventions based on their demonstrated ability to improve health, prevent disease and preserve function.
The 2026 Science-Based Healthy Ageing Framework
| Health domain | Priority | Practical focus |
|---|---|---|
| Cardiovascular health | Prevent major cardiovascular events. | Blood pressure, lipids, smoking cessation, exercise and appropriate medical treatment. |
| Metabolic health | Reduce metabolic disease risk. | Glucose regulation, healthy nutrition, physical activity and appropriate weight management. |
| Muscle and physical function | Preserve independence. | Resistance training, adequate protein, balance and mobility. |
| Brain and cognitive health | Maintain cognitive and functional capacity. | Sleep, exercise, social engagement, sensory health and management of vascular risk factors. |
| Preventive healthcare | Detect and manage meaningful health risks. | Evidence-based screening, vaccination and age-appropriate medical assessment. |
| Psychological and social wellbeing | Preserve purpose and quality of life. | Friendships, family, community, meaningful activities and emotional wellbeing. |
These are complementary priorities, not competing approaches. Effective healthy ageing requires an integrated strategy that recognises the relationship between physical, metabolic, cognitive and psychological health.
What About Biological-Age Testing?
Biological-age tests are increasingly marketed as tools for measuring how quickly an individual is ageing.
Depending on the technology, they may examine DNA methylation patterns, blood biomarkers, metabolic measurements or combinations of clinical variables.
These tests can be useful research tools, but they should not automatically be interpreted as accurate measurements of an individual's remaining lifespan.
Three questions are particularly important:
- Has the test been validated in large and diverse populations?
- Can changes in the score reliably predict meaningful clinical outcomes?
- Has the intervention that improves the score also been shown to improve health or extend healthy life?
A lower biological-age score is not necessarily proof that an intervention has slowed ageing in a clinically meaningful way.
A 2026 editorial in Nature Medicine, titled Anti-aging Interventions Need Less Hype and More Clinical Evidence, makes a similar point: the ageing field needs reliable biomarkers and stronger evidence for the safety and efficacy of anti-ageing treatments in humans.
Reference: Nature Medicine (11 August 2026).
8. What Should We Actually Optimise: Lifespan or Healthspan?
Two concepts are central to the longevity discussion:
Lifespan refers to the total number of years a person lives.
Healthspan refers to the period of life spent in relatively good health, with preserved physical, cognitive and functional capacity.
Extending lifespan without improving healthspan could mean extending the period spent living with disability, frailty or chronic disease.
For most people, the more meaningful objective is to preserve independence for as long as possible.
This includes:
- Being able to walk, climb stairs and perform everyday activities.
- Maintaining sufficient muscle strength and balance.
- Preserving cognitive function and emotional wellbeing.
- Reducing the likelihood of preventable cardiovascular and metabolic disease.
- Maintaining social relationships and a sense of purpose.
In other words, the goal should be to improve the quality of the years we gain.
9. A Better Way to Approach Longevity: Evidence Before Hype
The backlash against the longevity industry should lead to more thoughtful decision-making, not rejection of scientific progress.
Neither extreme is particularly helpful.
- The longevity industry sometimes promises more than science can currently deliver.
- Anti-longevity criticism can dismiss legitimate research along with commercial hype.
- Conventional preventive medicine remains important, but emerging research should not be rejected simply because it challenges established practices.
- Experimental treatments deserve scientific investigation, but should not be marketed as established therapies without appropriate evidence.
A sensible approach is to evaluate every intervention through the same set of questions.
The OneDayMD Longevity Evidence Checklist
Before adopting a longevity intervention, ask:
- What exactly is the intervention intended to achieve?
- Is the evidence based on laboratory experiments, animal studies, observational research or randomised clinical trials?
- Has it demonstrated a clinically meaningful benefit in humans?
- Does it improve lifespan, healthspan, physical function or only a biomarker?
- What are the known and potential adverse effects?
- Are there long-term safety data?
- Is the treatment appropriate for my age, health status and medical history?
- Are there financial conflicts of interest involving the researchers, companies or influencers promoting it?
- Could a simpler, cheaper and better-established intervention achieve a similar objective?
Our principle: A promising mechanism is not proof of clinical benefit. A compelling marketing story is not a substitute for human evidence.
10. The OneDayMD Perspective: Science-Led Longevity
At OneDayMD, we believe the longevity debate should not be framed as conventional medicine versus alternative longevity medicine.
Conventional medicine saves lives, while innovative and integrative approaches may help extend and enhance them. However, every intervention should be assessed according to the strength of its evidence, safety, clinical relevance and potential benefits.
Our aim is to examine both established preventive medicine and emerging health technologies without becoming an advocate for every new product, supplement, procedure or commercial trend.
We propose five interconnected pillars for a science-led longevity resource.
Pillar 1: Foundations of Longevity
- Nutrition and dietary patterns.
- Protein intake and muscle preservation.
- Aerobic conditioning and resistance training.
- Sleep and circadian health.
- Social connection and psychological wellbeing.
Pillar 2: Preventive and Precision Medicine
- Cardiovascular and metabolic risk assessment.
- Evidence-based screening and diagnostics.
- Biomarkers and laboratory testing.
- Personalised prevention strategies.
- AI-assisted health monitoring and decision support.
Pillar 3: Emerging Longevity Science
- Cellular senescence and senolytics.
- Epigenetics and biological ageing.
- Mitochondrial health.
- Regenerative medicine and stem cell research.
- Cellular reprogramming and emerging ageing pathways.
Pillar 4: Longevity Interventions
- Prescription medicines and off-label interventions.
- Supplements and nutritional compounds.
- Peptides and emerging therapeutics.
- Plasma-based interventions.
- Clinical trials and experimental procedures.
Pillar 5: Living Well While Ageing
- Healthy menopause and later-life health.
- Cognitive health and brain ageing.
- Mobility, balance and independence.
- Ageing without unnecessary body shame.
- Purpose, relationships and quality of life.
Each intervention should be evaluated according to its actual evidence, differentiating human clinical outcomes from animal studies, laboratory findings, biomarkers, observational associations and commercial claims.
Conclusion: The Real Goal Is to Live Better, Not Just Longer
The modern longevity movement has generated genuine scientific interest and investment. Research into cellular ageing, senescence, metabolic regulation, regenerative medicine and other biological mechanisms may eventually produce important medical advances.
But scientific progress should not be confused with commercial certainty.
We should be sceptical of products promising to reverse ageing, procedures claiming to rejuvenate the body without adequate clinical evidence, and diagnostic packages that turn every measurable biological variation into a health problem.
At the same time, we should not dismiss the value of preventive medicine, exercise, nutrition, social connection or carefully conducted research into ageing.
Emanuel reminds us that relationships and meaning matter. Benfield reminds us that ageing should not become another source of body dissatisfaction. Newman reminds us that demographic accuracy, research integrity and commercial transparency matter.
All three perspectives offer something valuable, provided their claims are evaluated critically and in context.
Perhaps the most sensible longevity strategy is also the least glamorous: maintain physical activity, preserve muscle, eat well, sleep adequately, manage genuine medical risks, nurture relationships and remain curious about life.
There is nothing wrong with wanting to live longer. There is nothing wrong with exploring scientific innovations that might help us achieve that goal.
But the pursuit of longevity should never become so demanding that we forget to enjoy the life we already have.
Healthspan before lifespan. Evidence before hype. Integration before ideology.
The ultimate measure of longevity is not simply how many birthdays we celebrate, but how well we are able to live the years in between.
References and Further Reading
- Ezekiel J. Emanuel. Eat Your Ice Cream: Six Simple Rules for a Long and Healthy Life. W. W. Norton, January 2026. Available on Amazon.
- Debra Benfield. Unapologetic Aging: How to Mend and Nourish Your Relationship with Your Body. December 2025. Available on Amazon.
- Saul Justin Newman. Morbid: Debunking Modern Longevity Science. MIT Press, July 2026. Available on Amazon.
- Gondo Y, et al. Age Verification of the Longest Lived Man in the World. Experimental Gerontology. 2017. PubMed.
- Saito Y, Yong V, Robine JM. The Mystery of Japan's Missing Centenarians Explained. Demographic Research. 2012. Full article.
- The Validity of Blue Zones Demography: A Response to Critiques. The Gerontologist. 2025. DOI.
- Bauer J, et al. Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association. 2013. PubMed.
- Wang F, et al. A Systematic Review and Meta-analysis of 90 Cohort Studies of Social Isolation, Loneliness and Mortality. Nature Human Behaviour. 2023. Full article.
- Associations Between Age Discrimination and Health and Wellbeing: Cross-sectional and Prospective Analysis of the English Longitudinal Study of Ageing. The Lancet Public Health. 2019. PubMed.
- Zantek ND, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice: The Tenth Special Issue. Journal of Clinical Apheresis. 2026. DOI.
- Anti-aging Interventions Need Less Hype and More Clinical Evidence. Nature Medicine. August 11, 2026. Full editorial.
- The Sinclair Lab. David A. Sinclair's Affiliations. Harvard Medical School. Disclosure information.
- Reject the Longevity Industry, Embrace Aging. The New York Times. 2026.
Medical Disclaimer
This article is intended for educational and informational purposes only. It is not personal medical advice, a diagnosis or a recommendation to start, stop or modify any medication, supplement or medical procedure. Experimental longevity interventions should be discussed with appropriately qualified healthcare professionals. Individual decisions should take into account medical history, established indications, potential risks and the quality of available evidence.
OneDayMD Research Team | Evidence-based health, integrated medicine and healthy ageing.
Comments